Cutting-Edge Research: New Frontiers in Cancer-Related Blood Clot Prevention
Published: Apr 29, 2024
Researchers are constantly working to improve blood clot prevention and treatment for cancer patients. Recent studies have revealed promising new approaches and insights.
Contents
Predicting Risk with Precision
New research is enhancing our ability to identify high-risk patients. The Vienna CATS score, developed from a large study, combines clinical factors with biomarkers to better predict clot risk. Another study found that genetic factors play a role, with certain inherited traits increasing clot risk in cancer patients. These advances may lead to more personalized prevention strategies.
Novel Prevention Strategies
Two major clinical trials, AVERT and CASSINI, have shown that newer oral anticoagulants can effectively prevent clots in high-risk outpatients receiving chemotherapy. These studies used the Khorana score to identify candidates for prevention. The results are changing clinical practice, offering an alternative to injectable medications for some patients.
Exploring New Treatments
Research is also focusing on new treatment approaches. Studies are investigating whether direct oral anticoagulants are as effective as traditional injections for treating cancer-related clots. Other research is exploring the potential of targeting specific clotting factors or using combination therapies. These studies aim to find treatments that are both more effective and easier for patients to use.
Frequently Asked Questions
Many focus on high-risk cancers, but aim for broader application.
Some findings are already changing practice; others need more research.
Yes, many centers offer trials for eligible patients.
Increasingly yes, especially when comparing oral vs. injectable treatments.
Key Takeaways
Ongoing research offers hope for better prevention and treatment of cancer-related blood clots.
Ask Doctronic about the latest research findings relevant to your specific cancer type and treatment plan.Related Articles
References
Carrier M, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med 2019; 380:711.
Khorana AA, et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med 2019; 380:720.
Always discuss health information with your healthcare provider.